Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV005400852 | SCV006060828 | likely pathogenic | Multiple endocrine neoplasia, type 2 | 2024-05-13 | criteria provided, single submitter | clinical testing | This missense deletes two nucleotides and inserts two nucleotides, replacing valine with leucine at codon 804 of the RET protein. Functional studies have reported that this variant resulted in intermediate level of transforming activity on ex vivo transfected cells (PMID: 9242375, 10445857) and to confer resistance to select kinase inhibitors (PMID: 26046350). To our knowledge, this variant has not been reported in individuals affected with RET-related disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Different variants resulting in the same amino acid change, c.2410G>C (p.Val804Leu) and c.2410G>T (p.Val804Leu), are well-documented pathogenic mutations (ClinVar Variation ID: 38613, 13946), indicating that valine at this position is important for RET protein function. Based on the available evidence, this variant is classified as Likely Pathogenic. |